Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Letrozole 6Cisplatin 5Tamoxifen 4Nivolumab 4Carboplatin 4Anastrozole 4ribociclib 3exemestane 3atezolizumab 3Vancomycin 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Bevacizumab 3trametinib 2toripalimab 2relatlimab 2pembrolizumab 2encorafenib 2dabrafenib 2binimetinib 2asciminib 2Vincristine 2Sodium Chloride 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Methotrexate 2Medroxyprogesterone Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Uric Acid × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡